• News
  • Stock Screener
  • Small Caps
  • Guru Portfolios
  • Review
  • News
  • Stock Screener
  • Small Caps
  • Guru Portfolios
  • Review
  • X (Twitter)
  • LinkedIn
Stock Screener·China·Healthcare·002349.SZ
Share

Jinghua Pharmaceutical Group Co., Ltd. Stocks

CN¥ 6.76Last Updated 13.07.2026

Issuer Rating

5/7
Performance

Favourable

Risk

Limited

Recommendation

Hold

Market Cap

CN¥ 805.86M

CN¥ 6.76
Key Takeaways

Risk factor

Meaningful price volatility

Data is available to registered users only
Data is available to registered users only

Profitability factor

Good margins and returns

Data is available to registered users only
Data is available to registered users only
Sign up to get free access to key risk and return factors, detailed company valuation, and analyst forecasts
Sign up to access all the key risk and return factors

Risks

  • Default risk
    Data is available to registered users only
  • Volatility
    Data is available to registered users only
  • Selling difficulty
    Data is available to registered users only
  • Stress test
    Data is available to registered users only
  • Country risks
    Data is available to registered users only
  • Other risks
    Data is available to registered users only
Sign up to access detailed risk analysis

About

Established in 1957 and headquartered in Nantong, China, Jinghua Pharmaceutical Group Co., Ltd. is a Chinese enterprise dedicated to the complete process of active pharmaceutical ingredients (APIs) and pharmaceutical intermediates, encompassing their research, development, manufacturing, and distribution. Its essential API offerings include a variety of compounds such as Phenylbutazone, Primidone, Phenobarbital, Fluorouracil, Propylthiouracil, Piroxicam, and Flucytosine. The company previously operated under the name Nantong Jinghua Pharmaceutical Co., Ltd.

Company Valuation

Fairly valued
4/7

Considering past and projected metrics, the stock is neither 'expensive' nor 'cheap' compared to its peers. Specifically, the stock is fairly valued on P/E, neutral on EV

Data is available to registered users only
Sign up to access detailed valuation

Risks

  • Default risk
    Data is available to registered users only
  • Volatility
    Data is available to registered users only
  • Selling difficulty
    Data is available to registered users only
  • Stress test
    Data is available to registered users only
  • Country risks
    Data is available to registered users only
  • Other risks
    Data is available to registered users only
Sign up to access detailed risk analysis

Trending

13.07.2026 20:30

Shares of a small software developer soared following news of its possible sale

13.07.2026 19:53

Trump announced the resumption of the blockade of the Strait of Hormuz against Iranian vessels

13.07.2026 19:20

Volkswagen has announced plans to lay off another 50,000 employees to cut costs

13.07.2026 18:52

Kazakhstani banks topped The Banker's rankings for profitability and capital growth in Asia

13.07.2026 18:41

Chipmakers' sell-off and a new escalation in Iran: How the market opened

X-channel

Buy

Sell

0 more stocks

Company

  • About
  • Contributors
  • Contacts
  • Legal Information

Social media

  • X (Twitter)
  • LinkedIn

Services

  • Stock Screener
  • Guru Portfolios
  • X (Twitter)
  • LinkedIn
Oninvest© 2026